Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease

Abstract

Kawasaki disease (KD) or Kawasaki syndrome is known as a vasculitis of small to medium-sized vessels, and coronary arteries are predominantly involved in childhood. Generally, 20–25% of untreated with IVIG and 3–5% of treated KD patients have been developed coronary artery lesions (CALs), such as dilatation and aneurysm. Understanding how coronary artery aneurysms (CAAs) are established and maintained in KD patients is therefore of great importance. Upon our previous genotyping data of 157 valid KD subjects, a genome-wide association study (GWAS) has been conducted among 11 (7%) CAA-developed KD patients to reveal five significant genetic variants passed pre-defined thresholds and resulted in two novel susceptibility protein-coding genes, which are NEBL (rs16921209 (P = 7.44 × 10⁻⁹; OR = 32.22) and rs7922552 (P = 8.43 × 10⁻⁹; OR = 32.0)) and TUBA3C (rs17076896 (P = 8.04 × 10⁻⁹; OR = 21.03)). Their known functions have been reported to associate with cardiac muscle and tubulin, respectively. As a result, this might imply their putative roles of establishing CAAs during KD progression. Additionally, various model analyses have been utilized to determine dominant and recessive inheritance patterns of identified susceptibility mutations. Finally, all susceptibility genes hit by significant genetic variants were further investigated and the top three representative gene-ontology (GO) clusters were regulation of cell projection organization, neuron recognition, and peptidyl-threonine phosphorylation. Our results help to depict the potential routes of the pathogenesis of CAAs in KD patients and will facilitate researchers to improve the diagnosis and prognosis of KD in personalized medicine.

About the Authors:

Ho-Chang Kuo

Contributed equally to this work with: Ho-Chang Kuo, Sung-Chou Li

Affiliation: Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Sung-Chou Li

Contributed equally to this work with: Ho-Chang Kuo, Sung-Chou Li

Affiliation: Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Mindy Ming-Huey Guo

Affiliation: Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Ying-Hsien Huang

Affiliation: Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Hong-Ren Yu

Affiliation: Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Fu-Chen Huang

Affiliation: Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Fuyong Jiao

Affiliation: Children's Hospital of Shaanxi Provincial People's Hospital and Jiaotong University, Xi'an, China

Hsing-Chun Kuo

Affiliation: Department of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan

Jorge Andrade

Affiliation: Center for Research Informatics, The University of Chicago, Chicago, Illinois, 60637, United States of America

Wen-Ching Chan

* E-mail: [email protected]

Affiliations Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Center for Research Informatics, The University of Chicago, Chicago, Illinois, 60637, United States of America

ORCID http://orcid.org/0000-0003-0034-7277

Introduction

Kawasaki disease (KD; OMIM 611775), also known as mucocutaneous lymph node syndrome, or Kawasaki syndrome, is one of the most common systemic vasculitis illnesses that preferentially occur in children younger than 5 years old. KD was first described by Dr. Tomisaku Kawasaki in 1967, and its diagnosis in clinics is primarily based upon a history of prolonged fever for at least five days along with four or more of the following manifestations: oral mucosa changes, conjunctivitis, enlargement of the cervical lymph nodes, swelling of the hands and feet and polymorphous skin rashes [1]. Up to date, higher incidence rates of KD have been reported in Asian populations; such as Japanese, Koreans, Taiwanese, and China, up to 239.6, 113.1, 66.2, and 49.4 per 100,000 children under five years old, respectively. Although the ethnic dominant pattern in KD has been identified, the incidence rate and the total number of patients with KD have been continuously increasing all over the place. Taken Together, this ethnic-preferential pattern implies that genetic factors might play a critical role as well as the environmental influence in the development and maintenance of KD in those susceptible hosts on genome scale.

As a vasculitis of the small to medium vessels, KD has a predilection for the involvement of the coronary arteries. Up to 25% of patients with KD may develop coronary artery lesions (CALs) if not given adequate treatment with intravenous immunoglobulin (IVIG), which in turn greatly increases the risk of coronary artery aneurysms (CAAs), and subsequent coronary artery thrombosis or myocardial infarction [2]. However, according to the current American Heart Association (AHA) guidelines, treatment with high-dose IVIG during the acute phase of the self-limited vasculitis in KD can substantially reduce the risk of coronary artery formation to 3–5% [3]. Namely, delayed diagnosis of KD and late treatment with IVIG is one of the critical risk factors for the development of CALs [4]. As an important complication of KD, other risk factors associated with CALs development include: children that are younger than 1 years old, prolonged fever duration or those who require more than one dose of IVIG, and those with higher inflammatory markers at baseline [5–8].

Although the underlying etiology of KD remains largely uncharacterized, clinical and epidemiology evidence indicates that an inflammatory response has been induced due to a ubiquitous infectious factor, subsequently host immune dysregulation frequently occurred in a small subset of genetically predisposed children. In immunopathogenosis, the activation of innate and acquired immunity has been reported to associate with KD patients in human and animal studies. In children with KD, CAAs usually develop within the first 4–6 weeks after disease onset [9]. Specifically, increased neutrophilic infiltration of the coronary vessels walls occur initially in the first two weeks after KD onset [10], followed by higher infiltration rate of natural killer cells and CD8 T cells afterwards [11]. On the other hand, from gene perspective, tumor necrosis factor α (TNF-α) appears to be a crucial mediator of inflammatory response in KD patients, by up-regulating the transcription of matrix metalloproteinases (MMP) such as MMP-9, which in turn leads to increased vessel wall elastin degradation and CAA formation [12]. Therapeutic blockage of TNF-α in murine model prevents the development of coronary artery disease, and has been used as an alternative therapy for children with IVIG-resistance in KD [12, 13].

The power of genome-wide association study (GWAS) makes it as one of the commonly used approaches to detect genomic loci individually or coincidently associated with the disease of interest in one high-throughput experiment on a genome-wide scale. In recent years, numerous GWASs have been conducted to identify single nucleotide polymorphisms (SNPs) significantly associated with the occurrence of KD among different populations, further resulting in the discovery of a number of susceptibility genes and their potential roles in the development and maintenance of KD [14–19]. It gives rise to a handful of SNPs being consistently reported in different GWASs of KD across different ethnics. For instance, rs28493229 and rs2290692 in ITPKC [15, 20–23], rs113420705 (formerly rs72689236) in CASP3 [24–27], rs1801274 in FCGR2A [15, 19, 28–31], rs4813003 and rs1569723 in CD40 [18, 19, 31], and rs2736340, rs2254546 and rs2618476 in BLK [18, 19, 28, 30–32] have been frequently revealed as significant genetic variants associated with the occurrence of KD in various GWASs. DNA methylation array data also identified an association between genomic hypomethylation of FCGR2A and susceptibility to KD and IVIG resistance [33]. Additionally, when considering the different outcomes upon KD subjects; for instance, the presence of CALs [16, 25, 34–39]/CAAs [40–45] or IVIG resistance [25, 26, 34, 46], a number of studies have been developed aiming to uncover the association between genetic variants and KD. Most of these studies inspected individual susceptibility genes and corresponding SNPs involved in the regulatory network of immune responses as well as cardiovascular-associated pathogenesis that might contribute to the formation of different outcomes or the response of treatments in KD.

The objectives of this study are to determine the genetic differences in CAA-developed (CAA+) KD patients using non-CAA developed (CAA-) KD as control, and further imply underlying molecular mechanisms, by which susceptibility genes located by significant polymorphisms might be associated with cardiac dysfunction. In this study, a comprehensive GWAS has been conducted guided by our previous high throughput genotyping microarray data [18] to reveal susceptibility loci associated with the development and maintenance of CAA in KD. The result of this study may be of interest to researchers in the KD community attempting to develop a more precise diagnosis or even prognosis of CAAs in KD patients.

Methods

Ethical statement

This study was approved by the Ethics Committee of the Institutional Review Board in Kaohsiung Chang Gung Memorial Hospital in Taiwan. Written informed consents were acquired from the Kawasaki disease patients’ parents or guardians according to institutional requirements and Declaration of Helsinki principles.

Study subjects and phenotype definition

Individuals fulfilling the diagnostic criteria of KD (n = 183) (including 146 patients without CAAs, 11 patients with CAAs, and 26 unclassified ones in our previous study [18]) were consecutively identified and recruited from Kaohsiung Chang Gung Memorial Hospital, Taiwan. CAA complications were determined from the echocardiograms according to the criteria provided by the Japanese Kawasaki Disease Research Committee: coronary arteries were identified as abnormal if the internal lumen diameter was ≥3 mm in children <5 years old or ≥4 mm in children ≥5 years old, if the internal diameter of a segment measured ≥1.5 times that of an adjacent segment, or if the coronary lumen was apparently irregular and the lesions were till noted 8 weeks after disease onset. Transient dilation of coronary artery was excluded.

SNP genotyping and quality control

Genomic DNA was extracted from blood using the Puregene DNA Isolation Kit (Gentra Systems). Each individual was genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 (with a total of 906,600 SNPs) according to the manufacturer’s protocols by the National Center for Genome Medicine (NCGM) at Academia Sinica, Taiwan [18]. Three major criteria were utilized to qualify valid SNPs including call rate (CR) >99%, minor allele frequency (MAF) >0.01, and the p-value of Hardy-Weinberg equilibrium (HWE) >1 × 10⁻⁴.

Statistical analysis

The allelic and genotypic frequency distributions of polymorphisms in KD patients according to the presence or absence of CAAs were determined through chi-square and Fisher’s exact analysis using PLINK software (v1.07, 10/Aug/2009) [47], respectively. Genotypes were obtained from direct counting followed by allele frequency calculations variables, and odds ratios (ORs) were calculated from allelic frequencies with a 95% confidence interval (95% CI). P-value of less than 0.001 was considered statistically significant, and adherence to the HWE constant was evaluated using a chi-square test with one degree of freedom. Furthermore, the dominant, recessive, and general genotypic models were employed to determine the genetic inheritance patterns of significant SNP candidates to susceptibility of CAA formation in KD patients [48]. Gene-ontology (GO) enrichment analysis has been calculated using chi-square distribution, and the collection of GO terms were further summarized into GO clusters using the web-based tool of REVIGO [49].

Results

Genetic association analysis between individual SNP and the risk of CAA complications in KD patients

To identify susceptibility genes associated with KD-associated CAAs, the presence and absence of CAAs occurred in 183 Taiwanese KD patients were linked toward our previous genotyping data [18]. After excluding 26 (14.21%) KD subjects without the determination of developing CAAs, 157 (85.79%) KD cases with the determination of CAA formation as listed in Table 1 were used in further analysis. In this study, a comprehensive GWAS has been applied to these valid genotyping data of KD patients consist of 96 (61.15%) males and 61 (38.85%) females (Table 1). In total, eleven (7.01%) KD patients with CAA formation were compared to the rest of 146 (92.99%) KD patients without CAA formation to identify significant genetic polymorphisms associated with the development and maintenance of CAAs in KD. Before identifying significant SNPs, customized criteria; including minor allele frequency (MAF), call rate (CR), and p-values of Hardy-Weinberg equilibrium (HWE), were applied to filter uncertain SNPs as described in the Methods, resulting in 559,609 (64.46%) out of 868,153 genotyped variants in the array remained and further qualified for the follow-up analysis. The genome-wide association results were plotted throughout chromosomes according to p-values calculated using chi-square tests as significance (Fig 1).

[Figure omitted. See PDF.]

Fig 1. Manhattan plot of the association between SNPs and susceptibility of CAA formation in KD.

The −log₁₀ P-values of significance shown in chromosomal order for qualified 559,602 SNPs tested for association in initial sample of 11 KD patients with CAA and 146 KD ones without CAA. The x-axis represents each of the SNPs used in the primary scan according to their genomic location. The y-axis indicates the −log₁₀ P-values of the trend test. Horizontal lines indicate the general and stringent thresholds of −log₁₀ P as 5 and 7, respectively.

https://doi.org/10.1371/journal.pone.0154943.g001

[Figure omitted. See PDF.]

Table 1. Subject statistics used in this study.

https://doi.org/10.1371/journal.pone.0154943.t001

A p-value of less than 0.001 was used as the threshold to specify the final set of significant genetic variants associated with CAA formation in KD patients, which in turn 720 (0.13%) sites were qualified for further analyses. When mapping these significant genetic polymorphisms toward gene structures, 31 (4.31%), 289 (40.14%), and 400 (55.56%) SNPs were identified to locate in genic, intronic, and intergenic regions, respectively. In addition, to identify potential susceptibility genes of the development of CAAs in KD patients, the gene hits of the top ranking non-intergenic SNPs were further investigated. The unique collection of genes located by significant genetic variants includes NEBL (Nebulette sarcomeric isoform; chr10:21,110,094–21,226,537), TUBA3C (Tubulin, Alpha 3c; chr13:18,645,918–18,653,936), SETBP1 (SET Binding Protein 1, chr18:40,535,138–40,898,771), ZNF618 (Zinc Finger Protein 618; chr9:115,678,383–115,858,696), MDGA1 (MAM Domain Containing Glycosylphosphatidyl Inositol (GPI) Anchor 1; chr6:37,708,262–37,773,744), MESP2 (Mesoderm Posterior Basic Helix-Loop-Helix Transcription Factor 2; chr15:88,120,593–88,122,986), FHAD1 (Forkhead-Associated (FHA) Phosphopeptide Binding Domain 1; chr1:15,446,355–15,597,209), and COL24A1 (Collagen, Type XXIV, Alpha 1; chr1:85,967,504–86,394,742) (Table 2). In this collection of susceptibility genes, NEBL (rs16921209 and rs7922552) and MDGA1 (rs12210919 and rs12211370) both have been hit only by two significant genetic polymorphisms from the top ranking list of mutations, whereas the genetic variant, rs17076896, is shared in the upstream promoter region between TUBA3C and LOC101928697. The putative functional roles of these genes in the formation of CAAs in KD will be discussed afterward.

[Figure omitted. See PDF.]

Table 2. Top 15 non-intergenic SNPs associated with susceptibility of CAA formation in KD.

https://doi.org/10.1371/journal.pone.0154943.t002

In addition to association analyses based upon individual major and minor alleles, the distribution of allele types (DD, Dd, and dd indicating major homozygous, heterozygous, and minor homozygous, respectively) were put into dominant, recessive, and general genotypic model analyses to identify the difference between cases and controls. Hence, the hit list of top ranking SNPs ordered by p-values computed using genotypic model has been identified and involved in genes including KCNH7 (Potassium Channel, Voltage Gated Eag Related Subfamily H, Member 7), TRAF5 (TNF Receptor-Associated Factor 5), NDUFA5 (NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 5), and MDGA2 (MAM Domain Containing Glycosylphosphatidyl-inositol (GPI) Anchor 2) (Table 3). When considering inheritance patterns, rs981840 (P = 2.93 × 10⁻⁵) and rs4383352 (P = 3.06 × 10⁻⁵) in KCNH7 and rs10137971, rs34362363, rs4900777, rs6572432, and rs7155197 (all p-values of 5.36 × 10⁻⁵) in MDGA2 were qualified as significant in dominant inheritance model, whereas rs4951523 (P = 3.34 × 10⁻⁵) and rs7550702 (P = 3.34 × 10⁻⁵) in TRAF5 and rs12666974 (P = 3.34 × 10⁻⁵) in NDUFA5 were more significant in recessive inheritance model.

[Figure omitted. See PDF.]

Table 3. Top 10 non-intergenic SNPs associated with susceptibility of CAA formation in KD using the general genotypic model.

https://doi.org/10.1371/journal.pone.0154943.t003

NEBL genetic polymorphisms may be related to KD-associated CAA complications

Nebulette protein has been reported to encode a 109 kDa nebulin homologous protein that is considerably expressed in cardiac muscle and is specifically localized in the sarcomeric Z-line of the heart [50]. Genetic variants in NEBL have been indicated to be causative for the occurrence of sudden cardiac death (SCD), in which an abrupt loss of heart function results in a sudden, unexpected death [51]. Moreover, it has been demonstrated to involve in mechanosensing and facilitate generation via the association with actin and tropomyosin-troponin complex [52]. In vitro and vivo studies, both have suggested its critical role in the stabilization of the thin-filament-Z-line alignment [50]. Missense abnormalities in NEBL have been illustrated to attribute to dilated cardiomyopathy (DCM) and endocardial fibroelastosis in humans and animal models [53]. Additionally, the observation of up-regulating genes responsive to cardiac stresses on nebulette-deficient mice has indicated its dispensable role on the regulation of normal cardiac function [50]. In this study, two genetic variants: rs16921209 (P = 7.44 × 10⁻⁹; OR = 32.22) and rs7922552 (P = 8.43 × 10⁻⁹; OR = 32.0) in the intronic regions of NEBL were revealed as significant SNPs to susceptibility of CAA formation in KD patients (Table 2). Furthermore, in linkage disequilibrium (LD) analysis, they were found to be in strong LD (r² = 0.99; Fig 2) at 10p12.31, in which the enclosed genomic region comprises multiple qualified SNP hits in the upstream introns of NEBL. As a result, this might imply that NEBL also play an important role on the development of CAAs during KD progression.

[Figure omitted. See PDF.]

Fig 2. Linkage disequilibrium plot of a region covering all SNPs of NEBL.

Two significant SNPs; rs16921209 (P = 7.44 × 10−9; OR = 32.22) and rs7922552 (P = 8.43 × 10−9; OR = 32.0), both located in the introns of NEBL are in high linkage disequilibrium (r² = 0.99), which might imply their co-interplay to susceptibility of CAA formation in KD patients.

https://doi.org/10.1371/journal.pone.0154943.g002

TUBA3C genetic variants to susceptibility of CAA occurrence in KD patients

The susceptibility variant of rs3818298 in T-Complex 1 (TCP1) has first been reported by Burgner et al. [14] to associate with KD risk and recently Lou et al. [31] has confirmed the pattern with additional independent cohort in a Chinese population. The protein encoded by TCP1 plays an important role in a member of the chaperonin of TCP1 ring complex in the functions of interacting with and structurally folding actin and tubulin. Instead of identification of TCP1, another tubulin family gene, TUBA3C has been identified with a significant SNP of rs17076896 (P = 8.04 × 10⁻⁹; OR = 21.03) located on its upstream promoter region in KD group with CAA formation (Table 2). To share the same promoter region, another uncharacterized gene, LOC101928697, on the downstream region with divergent transcription direction to TUBA3C might imply its putative function associated with the risk of CAA in KD patients. Additionally, the rs17790632 SNP in LOC101928697 has shown a high linkage pattern with rs17076896 in the shared promoter region with TUBA3C (r² = 0.90; Fig 3) in LD analysis, which it reflects that LOC101928697 might also serve as susceptibility gene to CAA formation during KD progression.

[Figure omitted. See PDF.]

Fig 3. Linkage disequilibrium plot of a region containing all SNPs of TUBA3C and LOC101928697.

The significant genetic variant of rs17076896 (P = 8.04 × 10−9; OR = 21.03) is located in the shared promoter region between TUBA3C and LOC101928697, which showed a high linkage disequilibrium (r² = 0.90) with another down-stream SNP, rs17790632, in LOC101928697.

https://doi.org/10.1371/journal.pone.0154943.g003

TNF- α and MMP associated genes may play a role in the formation of CAAs in KD

It has been reported that tumor necrosis factor α (TNF-α) plays a crucial role of inflammatory response in KD patients via up-regulating the transcription of matrix metalloproteinases (MMP) such as MMP-9, resulting in increased vessel wall elastin degradation and CAA formation [12]. In this study, we did reveal several associated, co-functional genes to susceptibility of this regulatory pathway. On one hand, two out of three qualified genetic variants (rs4951523 (P = 3.34 × 10⁻⁵) and rs7550702 (P = 3.34 × 10⁻⁵)) in TRAF5 (TNF Receptor-Associated Factor 5) have been associated with inheritance patterns as recessive genotype models (Table 3). It has been shown that TRAF5 is an important, versatile mediator beyond the TNFR-superfamily (SF); including viral mimics of its members, mediating specific cytokine receptor signals and innate immune receptor, as well as signal transductions of the T-cell receptor (TCR) complex [54]. Therefore, this reflects again that TNF and its co-regulatory genes like TRAF5 might play a crucial role in coronary artery disease.

Alternatively, it has been demonstrated by both animal models and clinical studies, matrix metalloproteinases (MMPs) such as MMP-9 are putative biomarkers for the function of cardiac remodeling, which are regulated by inflammatory signals to mediate changes in extracellular matrix [12]. Furthermore, within this family, some membrane-type MMPs (MT-MMPs) with lacks of an additional transmembrane domain or a small cytoplasmic tail, need to deliver signals by attaching to the plasma membrane using glycosylphosphatidyl-inositol (GPI) anchor proteins. In allelic association analysis, two specific SNPs of rs12210919 (P = 3.67 × 10⁻⁷; OR = 14.02) and rs12211370 (P = 1.62 × 10⁻⁶; OR = 16.00) in MDGA1 (MAM Domain Containing GPI Anchor 1) were identified as significant genetic variants in our top-ranking list (Table 2). Meanwhile, in general genotypic association analysis, at least five SNPs of rs10137971, rs34362363, rs4900777, rs6572432, and rs7155197 (all p-values of 5.36 × 10⁻⁵) in MDGA2 were defined as significantly dominant inheritance patterns (Table 3). Taken together, it might imply that MDGA gene family functions a putative regulatory role in association with the formation of CAA in KD patients.

GO cluster enrichment analysis revealed consistent results as in genetic association analysis

To focus on investigating the underlying mechanism of developing CAAs in KD patients, 263 protein-coding genes hit by 720 significant SNPs qualified from our genetic association analysis were collected, and gene ontology (GO) enrichment analysis has been applied to those susceptibility genes to determine over-represented GO terms. Accordingly, in total 162 enriched GOs were acquired and further summarized into higher levels of representative GO clusters to facilitate the interpretation of major functions related to CAA formation during KD progression upon genetic variants. Among the susceptibility genes highlighted above, NEBL and TUBA3C were associated with the GO clusters of regulation of cellular component size and protein complex assembly, respectively. TRAF5 was related to apoptotic process/death/positive regulation of cell proliferation and MDGA1/2 were contributed to neuron differentiation. The top three representative GO clusters were regulation of cell projection organization (P = 2.22 × 10⁻⁶), neuron recognition (P = 6.72 × 10⁻⁵), and peptidyl-threonine phosphorylation (P = 1.53 × 10⁻³) (Fig 4). For regulation of cell projection organization, most GO terms in this cluster were composed of cellular and extracellular organizations, involving in actin related genes. As a result, the global pattern has shown that genes involved in the formation of muscle cells like actin might function importantly in the development of CAAs in KD patients.

[Figure omitted. See PDF.]

Fig 4. Top three gene ontology enrichment groups associated with susceptibility of CAA formation in KD.

After gene ontology (GO) enrichment analysis, 162 over-represented GO terms were obtained and further summarized into GO clusters. The top three significant clusters were regulation of cell projection organization (P = 2.22 × 10⁻⁶), neuron recognition (P = 6.72 × 10⁻⁵), and peptidyl-threonine phosphorylation (P = 1.53 × 10⁻³).

https://doi.org/10.1371/journal.pone.0154943.g004

Potassium (K⁺) channels are the most heterogeneous and extensively recognized class of ion channels, and are widely identified as putative therapeutic targets in the treatment of neuron diseases like multiple sclerosis. They have been reported to be involved in a variety of cell types underlying both normal and pathophysiological processes, including nerve impulse propagation, muscle contraction and cellular activation [55]. They are comprised of dynamic pore-forming transmembrane proteins that selectively allow the flow current of potassium ions down an electrochemical gradient. In KD community, susceptibility genetic variants contained in Potassium channels associated genes have been reported to show a connection with the complication of CALs in KD patients [35]. In this study, a quantity of Potassium channels associated genes has been identified by containing significant SNPs to susceptibility of the development of CAAs in KD patients, resulting in the identification of neuron recognition in GO enrichment analysis (Fig 4). Hence, this represents that Potassium channels associated genes might facilitate CAA formation during KD progression.

For the over-representative cluster of peptidyl-threonine phosphorylation (Fig 4), one member gene TGFBR2 (Transforming Growth Factor, Beta Receptor II) has been reported to associate with the pathogenesis of KD and CALs [56]. Meanwhile, another member gene CAMK2D (Calcium/Calmodulin-Dependent Protein Kinase II Delta) has been demonstrated to involve in a plausible biological network and to decrease transcript abundance in the acute phase of KD [14, 31]. Therefore, some critical genes identified to act significantly in KD with CALs might also perform alternative role in the pathogenesis of CAAs in KD patients.

Discussion and Conclusion

Due to the obscurity of the causes resulting in KD, there is no existing clinical method to prevent its occurrence. Moreover, KD remains the leading cause of acquired heart damages in children younger than 5 years old. Many studies have been dedicated to investigate critical factors in the development of CAAs during KD progression. Briefly, in 2005 Matsubara et al. reported that histological findings in KD including vasculitis, endothelial necrosis, and infiltration of mononuclear cells into blood vessels [57]. In previous studies, plasma levels of inflammatory cytokines (TNF-α, IL-4, IL-5, IL-6, IL-17, IL-31, and IP-10) [7, 8, 58–62], chemokines and adhesion molecules were elevated at the acute stage of KD [57]. Macrophage colony-stimulating factor (M-CSF) has been performed to play a critical role in the pathogenesis of KD and can be used as an indicator for the risks of valvulitis and coronary arteritis [11, 63]. Guiducci et al. reported that microparticles (MPs) may develop from endothelial damage and cell activation is significantly increased as well as endothelial cells and T cells are the major sources [64]. Taken together, macrophages and platelets also get recruited to this site of vasculitis or may play a role in the immunopathogenesis of KD.

In this study, a comprehensive GWAS has been conducted upon 157 valid KD patients to identify susceptibility genetic polymorphisms and their corresponding genes as major risk factors to CAA formation in KD patients. Although potential links between susceptibility loci identified in this study and the formation of CAAs in KD patients still remain gaps for researchers to clarify. However, this study provides various hints for researchers in KD community to postulate that the essential underlying mechanism of the pathogenesis of CAAs in KD might be associated with genes related to cardiac muscles and vessels. Accordingly, our results indicate that susceptibility genes (e.g., NEBL, TUBA3C, TRAF5, and MDGA1/2) carried with certain significant genetic polymorphisms might play important roles in the risk of CAA complications in KD patients from genetic perspective. Furthermore, from GO perspective, these susceptibility loci were enriched in the functions related to regulation of cell projection organization, neuron recognition, and peptidyl-threonine phosphorylation.

To examine the connection between genetic alternations and gene expression, the susceptibility genes highlighted in this study were investigated in recent transcriptome studies related to KD CAA. For instance, according to the 1,074 DEGs reported by Rowley et al. [65], most of our reported genes with significant genetic variants were not classified as dysregulation ones. Accordingly, the authors claimed that most genes in cytokine and growth factor family might not play the most prominent role in KD CAA from the transcriptome perspective. However, as explained in the same study, the interplay between genetic alternations, gene expression, and protein production are not always associated with each other. Therefore, more integrative studies (genomics, transcriptomics and proteomics together) will be needed to help us understand the underlying pathogenesis of KD CAA.

Recently, IVIG treatment has been demonstrated to associate with the inhibition of TNF-α-induced MMP9 expression and shows a protective effect in KD CAA [66]. Some IVIG-resistant patients have been reported with a higher risk of developing coronary artery abnormalities in KD [67]. Infliximab, as an anti-cytokine therapy, leverages the blocking of TNF-α pathway to provide another treatment solution to KD patients with IVIG resistance [68]. Therefore, although in the recent transcriptomic study, genes from TNF-α family were shown as no up-regulation in KD CAA [65], genetic alternations [69], animal models [59, 70–72], and clinical therapy [66, 68] associated with these genes have been keeping to report as susceptibility factors and consequences to KD CAA. This remains an open question about the interplay among different levels to the pathogenesis of KD CAA. As a result, our results help to gain insights into the potential routes of the development of CAAs in KD and might benefit researchers in KD community to improve the diagnosis and prognosis of KD in personalized medicine.

Supporting Information

[Figure omitted. See PDF.]

S1 File. GWAS table containing all non-intergenic SNPs of KD CAA in this study.

Major (D) and minor (d) alleles were shown in the Alleles column. The major SNP allele frequency in cases and controls were indicated in the F_A and F_U columns, respectively. OR represents the odds ratio. The p-values of Chi-squared test were indicated in the P column.

https://doi.org/10.1371/journal.pone.0154943.s001

(XLSX)

Acknowledgments

We thank the Genomics & Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital for technical supports, as well as Kawasaki disease center, Kaohsiung Chang Gung Memorial Hospital for providing experimental data. This was supported by the grants from Kaohsiung Chang Gung Memorial Hospital (CMRPG8C1082, CMRPG8B0212, CMRPG8D1561 and CMRPG8D0521, CLRPG8D0112, and CMRPG8D0032). This study was partly supported by a grant from the Ministry of Science and Technology, Taiwan (MOST 102-2314-B-182-053-MY3). The Center for Research Informatics is funded by the Biological Sciences Division at the University of Chicago with additional funding provided by the Institute for Translational Medicine, CTSA grant number UL1 TR000430 from the National Institutes of Health.

Author Contributions

Conceived and designed the experiments: Ho-Chang Kuo WCC. Performed the experiments: Ho-Chang Kuo MMG YHH Hsing-Chun Kuo. Analyzed the data: WCC. Contributed reagents/materials/analysis tools: Ho-Chang Kuo MMG YHH HRY FCH FJ. Wrote the paper: WCC YHH JA Ho-Chang Kuo. Organised and collected data: SCL.

Citation: Kuo H-C, Li S-C, Guo MM-H, Huang Y-H, Yu H-R, Huang F-C, et al. (2016) Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease. PLoS ONE 11(5): e0154943. https://doi.org/10.1371/journal.pone.0154943

References

1. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–44. pmid:15302199.

2. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996;28(1):253–7. pmid:8752822.

3. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;(4):CD004000. pmid:14584002.

4. Minich LL, Sleeper LA, Atz AM, McCrindle BW, Lu M, Colan SD, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics. 2007;120(6):e1434–40. pmid:18025079.

5. Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr. 2007;166(5):421–5. pmid:17033807.

6. Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, et al. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr. 2009;168(11):1315–21. pmid:19159953.

7. Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, et al. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease. Pediatr Allergy Immunol. 2009;20(3):266–72. pmid:19438983.

8. Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS. Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 2012;53(1):4–11. pmid:22348488.

9. Lin MT, Sun LC, Wu ET, Wang JK, Lue HC, Wu MH. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous gamma-immunoglobulin therapy. Arch Dis Child. 2015;100(6):542–7. pmid:25564534.

10. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41(11):785–97. pmid:1785339.

11. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis. 2001;184(7):940–3. pmid:11528596.

12. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010;22(5):551–60. pmid:20616737.

13. Tacke CE, Burgner D, Kuipers IM, Kuijpers TW. Management of acute and refractory Kawasaki disease. Expert Rev Anti Infect Ther. 2012;10(10):1203–15. pmid:23199405.

14. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 2009;5(1):e1000319. pmid:19132087; PubMed Central PMCID: PMC2607021.

15. Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011;43(12):1241–6. pmid:22081228.

16. Kim JJ, Hong YM, Sohn S, Jang GY, Ha KS, Yun SW, et al. A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet. 2011;129(5):487–95. pmid:21221998.

17. Tsai FJ, Lee YC, Chang JS, Huang LM, Huang FY, Chiu NC, et al. Identification of novel susceptibility Loci for kawasaki disease in a Han chinese population by a genome-wide association study. PLoS One. 2011;6(2):e16853. pmid:21326860; PubMed Central PMCID: PMC3033903.

18. Lee YC, Kuo HC, Chang JS, Chang LY, Huang LM, Chen MR, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet. 2012;44(5):522–5. pmid:22446961.

19. Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012;44(5):517–21. pmid:22446962.

20. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. pmid:18084290; PubMed Central PMCID: PMC2876982.

21. Kuo HC, Yang KD, Juo SH, Liang CD, Chen WC, Wang YS, et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One. 2011;6(4):e17370. pmid:21533171; PubMed Central PMCID: PMC3077380.

22. Lou J, Xu S, Zou L, Zhong R, Zhang T, Sun Y, et al. A functional polymorphism, rs28493229, in ITPKC and risk of Kawasaki disease: an integrated meta-analysis. Mol Biol Rep. 2012;39(12):11137–44. pmid:23065250.

23. Peng Q, Chen C, Zhang Y, He H, Wu Q, Liao J, et al. Single-nucleotide polymorphism rs2290692 in the 3'UTR of ITPKC associated with susceptibility to Kawasaki disease in a Han Chinese population. Pediatr Cardiol. 2012;33(7):1046–53. pmid:22361738.

24. Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, et al. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J Hum Genet. 2011;56(2):161–5. pmid:21160486.

25. Kuo HC, Hsu YW, Wu CM, Chen SH, Hung KS, Chang WP, et al. A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki disease. PLoS One. 2013;8(7):e69685. pmid:23894522; PubMed Central PMCID: PMC3722201.

26. Onouchi Y, Suzuki Y, Suzuki H, Terai M, Yasukawa K, Hamada H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 2013;13(1):52–9. pmid:21987091.

27. Wang W, Lou J, Zhong R, Qi YQ, Shen N, Lu XZ, et al. The roles of Ca2+/NFAT signaling genes in Kawasaki disease: single- and multiple-risk genetic variants. Sci Rep. 2014;4:5208. pmid:24903211; PubMed Central PMCID: PMC4047536.

28. Yan Y, Ma Y, Liu Y, Hu H, Shen Y, Zhang S, et al. Combined analysis of genome-wide-linked susceptibility loci to Kawasaki disease in Han Chinese. Hum Genet. 2013;132(6):669–80. pmid:23456091.

29. Duan J, Lou J, Zhang Q, Ke J, Qi Y, Shen N, et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis. PLoS One. 2014;9(8):e103329. pmid:25093412; PubMed Central PMCID: PMC4122468.

30. Wang W, Lou J, Lu XZ, Qi YQ, Shen N, Zhong R, et al. 8p22-23-rs2254546 as a susceptibility locus for Kawasaki disease: a case-control study and a meta-analysis. Sci Rep. 2014;4:4247. pmid:24577620; PubMed Central PMCID: PMC3937782.

31. Lou J, Zhong R, Shen N, Lu XZ, Ke JT, Duan JY, et al. Systematic confirmation study of GWAS-identified genetic variants for Kawasaki disease in a Chinese population. Sci Rep. 2015;5:8194. pmid:25645453; PubMed Central PMCID: PMC4314627.

32. Chang CJ, Kuo HC, Chang JS, Lee JK, Tsai FJ, Khor CC, et al. Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLoS One. 2013;8(8):e72037. pmid:24023612; PubMed Central PMCID: PMC3758326.

33. Kuo HC, Chang JC, Kuo HC, Yu HR, Wang CL, Lee CP, et al. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array. Arthritis Rheumatol. 2015;67(3):828–36. pmid:25470559.

34. Kim JJ, Hong YM, Yun SW, Han MK, Lee KY, Song MS, et al. Assessment of risk factors for Korean children with Kawasaki disease. Pediatr Cardiol. 2012;33(4):513–20. pmid:22105492.

35. Kim JJ, Park YM, Yoon D, Lee KY, Seob Song M, Doo Lee H, et al. Identification of KCNN2 as a susceptibility locus for coronary artery aneurysms in Kawasaki disease using genome-wide association analysis. J Hum Genet. 2013;58(8):521–5. pmid:23677057.

36. Lin MT, Hsu CL, Taiwan Pediatric CVG, Chen PL, Yang WS, Wang JK, et al. A genome-wide association analysis identifies novel susceptibility loci for coronary arterial lesions in patients with Kawasaki disease. Transl Res. 2013;161(6):513–5. pmid:23454411.

37. Bowles NE, Arrington CB, Hirono K, Nakamura T, Ngo L, Wee YS, et al. Kawasaki disease patients homozygous for the rs12252-C variant of interferon-induced transmembrane protein-3 are significantly more likely to develop coronary artery lesions. Mol Genet Genomic Med. 2014;2(4):356–61. pmid:25077179; PubMed Central PMCID: PMC4113277.

38. Kuo HC, Hsu YW, Lo MH, Huang YH, Chien SC, Chang WC. Single-nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease. PLoS One. 2014;9(3):e91118. pmid:24621571; PubMed Central PMCID: PMC3951297.

39. Hsueh KC, Lin YJ, Chang JS, Wan L, Tsai FJ. BTNL2 gene polymorphisms may be associated with susceptibility to Kawasaki disease and formation of coronary artery lesions in Taiwanese children. Eur J Pediatr. 2010;169(6):713–9. pmid:19882345.

40. Chen YT, Liao WL, Lin YJ, Chen SY, Tsai FJ. Association between SRC-1 gene polymorphisms and coronary artery aneurysms formation in Taiwanese children with Kawasaki disease. J Clin Lab Anal. 2014;28(6):435–9. pmid:24652666.

41. Lin YJ, Chang JS, Liu X, Tsang H, Lin TH, Liao CC, et al. Genetic variants of glutamate receptor gene family in Taiwanese Kawasaki disease children with coronary artery aneurysms. Cell Biosci. 2014;4(1):67. pmid:25485088; PubMed Central PMCID: PMC4258047.

42. Lin YJ, Liu X, Chang JS, Chien WK, Chen JH, Tsang H, et al. Coronary artery aneurysms occurrence risk analysis between Kawasaki disease and LRP1B gene in Taiwanese children. Biomedicine (Taipei). 2014;4:10. pmid:25520923; PubMed Central PMCID: PMC4265017.

43. Lin YJ, Wan L, Wu JY, Sheu JJ, Lin CW, Lan YC, et al. HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. Arthritis Rheum. 2009;60(2):604–10. pmid:19180512.

44. Huang YC, Lin YJ, Chang JS, Chen SY, Wan L, Sheu JJ, et al. Single nucleotide polymorphism rs2229634 in the ITPR3 gene is associated with the risk of developing coronary artery aneurysm in children with Kawasaki disease. Int J Immunogenet. 2010;37(6):439–43. pmid:20618519.

45. Lin YJ, Chang JS, Liu X, Hung CH, Lin TH, Huang SM, et al. Association between GRIN3A gene polymorphism in Kawasaki disease and coronary artery aneurysms in Taiwanese children. PLoS One. 2013;8(11):e81384. pmid:24278430; PubMed Central PMCID: PMC3838481.

46. Shendre A, Wiener HW, Zhi D, Vazquez AI, Portman MA, Shrestha S. High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study. Genes Immun. 2014;15(8):534–42. pmid:25101798; PubMed Central PMCID: PMC4257866.

47. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. pmid:17701901; PubMed Central PMCID: PMC1950838.

48. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. Nat Protoc. 2011;6(2):121–33. pmid:21293453; PubMed Central PMCID: PMC3154648.

49. Supek F, Bosnjak M, Skunca N, Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011;6(7):e21800. pmid:21789182; PubMed Central PMCID: PMC3138752.

50. Mastrototaro G, Liang X, Li X, Carullo P, Piroddi N, Tesi C, et al. Nebulette knockout mice have normal cardiac function but show Z-line widening and upregulation of cardiac stress markers. Cardiovasc Res. 2015. pmid:25987543.

51. Chopra N, Knollmann BC. Genetics of sudden cardiac death syndromes. Curr Opin Cardiol. 2011;26(3):196–203. pmid:21430528; PubMed Central PMCID: PMC3145336.

52. Maiellaro-Rafferty K, Wansapura JP, Mendsaikhan U, Osinska H, James JF, Taylor MD, et al. Altered regional cardiac wall mechanics are associated with differential cardiomyocyte calcium handling due to nebulette mutations in preclinical inherited dilated cardiomyopathy. J Mol Cell Cardiol. 2013;60:151–60. pmid:23632046; PubMed Central PMCID: PMC3683841.

53. Purevjav E, Varela J, Morgado M, Kearney DL, Li H, Taylor MD, et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol. 2010;56(18):1493–502. pmid:20951326; PubMed Central PMCID: PMC2957670.

54. Hildebrand JM, Yi Z, Buchta CM, Poovassery J, Stunz LL, Bishop GA. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev. 2011;244(1):55–74. pmid:22017431; PubMed Central PMCID: PMC3202299.

55. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8(12):982–1001. pmid:19949402; PubMed Central PMCID: PMCPMC2790170.

56. Choi YM, Shim KS, Yoon KL, Han MY, Cha SH, Kim SK, et al. Transforming growth factor beta receptor II polymorphisms are associated with Kawasaki disease. Korean J Pediatr. 2012;55(1):18–23. pmid:22359526; PubMed Central PMCID: PMC3282214.

57. Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141(3):381–7. pmid:16045726; PubMed Central PMCID: PMCPMC1809464.

58. Tseng WN, Lo MH, Guo MM, Hsieh KS, Chang WC, Kuo HC. IL-31 associated with coronary artery lesion formation in Kawasaki disease. PLoS One. 2014;9(8):e105195. pmid:25122210; PubMed Central PMCID: PMCPMC4133352.

59. Lin IC, Kuo HC, Lin YJ, Wang FS, Wang L, Huang SC, et al. Augmented TLR2 expression on monocytes in both human Kawasaki disease and a mouse model of coronary arteritis. PLoS One. 2012;7(6):e38635. pmid:22737215; PubMed Central PMCID: PMCPMC3380902.

60. Kuo HC, Yang YL, Chuang JH, Tiao MM, Yu HR, Huang LT, et al. Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease. J Clin Immunol. 2012;32(4):746–52. pmid:22392047.

61. Ko TM, Kuo HC, Chang JS, Chen SP, Liu YM, Chen HW, et al. CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease. Circ Res. 2015;116(5):876–83. pmid:25605650.

62. Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015;70(3):310–8. pmid:25585854.

63. Igarashi H, Hatake K, Shiraishi H, Samada K, Tomizuka H, Momoi MY. Elevated serum levels of macrophage colony-stimulating factor in patients with Kawasaki disease complicated by cardiac lesions. Clin Exp Rheumatol. 2001;19(6):751–6. pmid:11791654.

64. Guiducci S, Ricci L, Romano E, Ceccarelli C, Distler JH, Miniati I, et al. Microparticles and Kawasaki disease: a marker of vascular damage? Clin Exp Rheumatol. 2011;29(1 Suppl 64):S121–5. pmid:21385556.

65. Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015;16:1076. pmid:26679344; PubMed Central PMCID: PMCPMC4683744.

66. Zhou C, Huang M, Xie L, Shen J, Xiao T, Wang R. IVIG inhibits TNF-alpha-induced MMP9 expression and activity in monocytes by suppressing NF-kappaB and P38 MAPK activation. Int J Clin Exp Pathol. 2015;8(12):15879–86. pmid:26884859; PubMed Central PMCID: PMCPMC4730072.

67. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17(12):1144–8. pmid:9877364.

68. Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Pediatr Infect Dis J. 2016;35(4):457–9. pmid:26673981.

69. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol. 2003;23(4):576–81. pmid:12692003.

70. Lin IC, Suen JL, Huang SK, Huang SC, Huang HC, Kuo HC, et al. Dectin-1/Syk signaling is involved in Lactobacillus casei cell wall extract-induced mouse model of Kawasaki disease. Immunobiology. 2013;218(2):201–12. pmid:22633994.

71. Oharaseki T, Yokouchi Y, Yamada H, Mamada H, Muto S, Sadamoto K, et al. The role of TNF-alpha in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol. 2014;24(1):120–8. pmid:24261768.

72. Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RS. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol. 2009;157(2):300–9. pmid:19604270; PubMed Central PMCID: PMCPMC2730856.